Short description
Cascadian Therapeutics is a bio-pharmaceutical company that researches, develops, and sells therapeutic products for treatment of cancer.
Description
Cascadian Therapeutics, a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States.
The company lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It is also developing Checkpoint kinase 1, a protein kinase that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress.
In addition, the company focuses on the development of novel antibodies and T-cell immunoreceptor with Ig and ITM domains, an inhibitory receptor expressed on T-cells and NK cells that negatively regulate immune response to cancers. It has a license agreement with Array BioPharma Inc. to develop, manufacture and commercialize tucatinib; research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; and collaboration agreement with Adimab LLC for the discovery of novel antibodies against d immunotherapy targets in oncology.
Last funding
Noaccess
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Seattle, Washington, United States, North America
Founded on
January 1, 1985
Exited on
November 29, 1991
Went public on
November 29, 1991
Delisted on
March 9, 2018
Stock symbol
CASC
Non-profit?
No
Acquired?
No
Employees count
51-100
Revenue range
$7890 - 12340
Sign in for full access
Investors
No Way, Noaccess, Absolutely Noaccess, Absolutely Noaccess, Noway Youcantaccess, Noaccess, Cannot Access, No Way, Nopepepe, Blurry Noaccess, Noaccess, Noaccess
Sign in for full access